IBIdris Bahce

Idris Bahce

*This is an algorithmically generated author record based on publicly available information.

Idris Bahce has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Adriaan A. Lammertsma

    University Medical Center Groningen, University of Groningen

    3 shared publications
  • E. Thunnissen

    Pathology, VU University Medical Center, Amsterdam/NL

    2 shared publications
  • Egbert F. Smit

    Department of Pulmonary Diseases, VU University Medical Center, PO Box 7057, 1007MB, Amsterdam, The Netherlands

    2 shared publications
  • Maqsood Yaqub

    Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

    2 shared publications
  • N. Harry Hendrikse

    Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

    2 shared publications
  • Robert C. Schuit

    Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

    2 shared publications

Latest Publications

  • MA 05.07 Whole Body PD-1 and PD-L1 PET in Pts with NSCLC

    by A. Niemeijer, E. Smit, G. Van Dongen, A.D. Windhorst, M. Huisman, N. Hendrikse, I. Bahce, D. Lueng, R. Smith, W. Hayes, et al.


  • P2.02-024 False Positivity Due to Polysomy in Fluorescence in Situ Hybridization

    by A.L. Görtz, S. Finn, L. Bubendorf, I. Bahce, B. Witte, E. Thunnissen

  • Open Access

    Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET

    by I. Bahce, M. Yaqub, E.F. Smit, A.A. Lammertsma, G.A.M.S. van Dongen, N.H. Hendrikse


  • Open Access

    Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC

    by Idris Bahce, Maqsood Yaqub, Hanane Errami, Robert C. Schuit, Patrick Schober, Erik Thunnissen, Albert D. Windhorst, Adriaan A. Lammertsma, Egbert F. Smit, N. Harry Hendrikse

    In non-small cell lung cancer (NSCLC) patients off erlotinib therapy, positron emission tomography (PET) using [11C]erlotinib distinguished epidermal growth factor receptor (EGFR) mutations from wild-type EGFR. However, tumor uptake of [11C]erlotinib during erlotinib therapy is unknown. Therefore, the aims of this study were to evaluate tumor [11C]erlotinib uptake in NSCLC patients both on and off erlotinib therapy, to evaluate the effect of erlotinib therapy on tumor perfusion and its correlation to tumor [11C]erlotinib uptake, and also, to investigate simplified uptake parameters using arterial and venous blood samples. Ten patients were to be scanned twice with a 1–2-week interval, i.e., on (E+) and off (E−) erlotinib therapy. Each procedure consisted of a low-dose CT scan, a 10-min dynamic [15O]H2O PET scan, and a 60-min dynamic [11C]erlotinib PET scan with arterial and venous sampling at six time points. In patients(E+), the optimal compartment model was analyzed using Akaike information criterion. In patients(E−), the uptake parameter was the volume of distribution (V T), estimated by using metabolite-corrected plasma input curves based on image-derived input functions and discrete arterial and venous blood samples. Tumor blood flow (TBF) was determined by rate constant of influx (K1) of [15O]H2O using the 1T2k model and correlated with V T and K1 values of [11C]erlotinib. The investigated simplified parameters were standardized uptake value (SUV) and tumor-to-blood ratio (TBR) at 40–60 min pi interval. Of the 13 patients included, ten were scanned twice. In patients(E+), [11C]erlotinib best fitted the 2T4k model with V T. In all patients, tumor V T(E+) was lower than V T(E−) (median V T(E−) = 1.61, range 0.77–3.01; median V T(E+) = 1.17, range 0.53–1.74; P = 0.004). Using [15O]H2O, five patients were scanned twice. TBF did not change with erlotinib therapy, TBF showed a positive trend towards correlation with [11C]erlotinib K1, but not with V T. TBR40–50 and TBR50–60, using both arterial and venous sampling, correlated with V T(E−) (all r s >0.9, P < 0.001), while SUV did not. In patients off and on therapy, venous TBR underestimated arterial TBR by 26 ± 12 and 9 ± 9 %, respectively. In patients on erlotinib in therapeutic dose, tumor V T decreases with high variability, independent of tumor perfusion. For simplification of [11C]erlotinib PET scanning protocols, both arterial and venous TBR 40–60 min post injection can be used; however, arterial and venous TBR values should not be interchanged as venous values underestimate arterial values. Registered at the Netherlands Trial Registry: NTR3670 .


  • Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status

    by Idris Bahce, Egbert F. Smit, Mark Lubberink, Astrid A. M. van der Veldt, Maqsood Yaqub, Albert D. Windhorst, Robert C. Schuit, Erik Thunnissen, Daniëlle A. M. Heideman, Pieter E. Postmus, et al.

    Purpose: To evaluate whether, in patients with non–small cell lung carcinoma (NSCLC), tumor uptake of [11C]erlotinib can be quantified and imaged using positron emission tomography and to assess whether the level of tracer uptake corresponds with the presence of activating tumor EGF receptor (EGFR) mutations.


  • Effects of the antiangiogenic drug bevacizumab on tumor perfusion and drug delivery of 11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): Implications for scheduling of antiangiogenic agents.

    by E. F. Smit, M. Lubberink, I. Bahce, M. Walraven, M. P. de Boer, H. N. Greuter, N. H. Hendrikse, J. Eriksson, A. D. Windhorst, P. E. Postmus, et al.

    3059 Background: Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in patients with advanced-stage NSCLC cancer. It has been hypothesized that pre-treatment with anti-angiogenic drugs may transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy (Nat Med 2001;7:987-9). The purpose of the present study was to investigate this concept in NSCLC patients using a perfusion tracer ([15O]H2O), radiolabeled chemotherapy ([11C]docetaxel) and positron emission tomography (PET) before and after a single infusion of bevacizumab. Methods: A total of 70 PET scans were scheduled in 10 NSCLC patients. Patients underwent dynamic PET scans with [15O]H2O and [11C]docetaxel before, and at 5 hours and 4 days after IV administration of bevacizumab (15 mg·kg-1). An additional [15O]H2O scan was performed at 2 hours. Systemic effects of bevacizumab were investigated by assessing: (1) plasma levels of vascular endothelial growth factor (VEGF) using ELISA kits, (2) blood pressure, (3) cardiac output using [15O]H2O, and (4) microcirculation in the skin using capillaroscopy. Results: Two hours after bevacizumab administration, tumor perfusion did not change (Wilcoxon Signed Ranks test , P = 0.89). At 5 hours, however, both tumor perfusion and the net influx rate constant of [11C]docetaxel decreased significantly (P < 0.05 for both). These changes persisted until day 4 (P < 0.01 for both). Changes in tumor parameters were accompanied by a rapid decrease in circulating VEGF at 3 hours (P < 0.05) and a decline in cardiac output at 4 days (P = 0.05). The other systemic parameters remained unchanged. Conclusions: A single dose of bevacizumab induces a rapid and significant decline in tumor perfusion and [11C]docetaxel delivery in NSCLC tumors. These rapid changes in tumor parameters are not due to changes in cardiovascular parameters. The findings of the present study highlight the importance of drug scheduling for enhancing drug delivery to tumors and advocate further studies to optimize scheduling of anti-angiogenic drugs.